Galapagos NV (GLPG)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman, Interim Head of R&D | 1.4M | -- | 1962 |
| Mr. Thad Huston | Executive VP, CFO & COO | -- | -- | 1971 |
| Ms. Sofie Van Gijsel | Head of Investor Relations | -- | -- | -- |
| Ms. Valeria Cnossen | Executive VP & General Counsel | -- | -- | 1974 |
| Marieke Vermeersch | Head of Corporate Communication | -- | -- | -- |
| Ms. Annelies Missotten | Executive VP & Chief Human Resources Officer | -- | -- | 1973 |
| Ms. Ellen Van Der Aar | Head of Development | -- | -- | -- |
| Mr. Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Business Development | -- | -- | -- |
| Ms. Alice Dietrich | Head of Medical Affairs | -- | -- | -- |
| Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D. | Head of Small Molecules Discovery & Senior VP | -- | -- | -- |
Galapagos NV
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 683
Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Corporate Governance
Upcoming Events
October 30, 2024 at 10:59 AM UTC
Galapagos NV Earnings Date